{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-001755","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.646979+00:00","generated_at":"2026-05-16T10:47:03.093820+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Alnylam reports preliminary 2025 net product revs $2,987M (+81% YoY); guides 2026 revs $4.9B-$5.3B","bullets":["Preliminary 2025 net product revenue $2,987M (81% growth vs 2024); TTR franchise $2,487M (103% growth).","2026 combined net product revenue guidance $4.9B–$5.3B (71% growth at midpoint); TTR guidance $4.4B–$4.7B.","New 'Alnylam 2030' strategy targets 25%+ total revenue CAGR and ~30% non-GAAP operating margin by 2030.","Pipeline goals: nucresiran Phase 3 in ATTR-CM/polyneuropathy; mivelsiran Phase 2 enrollment in H1 2026.","Preliminary Q4 2025: total TTR revs ~$859M (AMVUTTRA $827M, ONPATTRO $32M); total rare revs ~$137M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-001755","json":"https://secwatch.observer/filing/0001628280-26-001755.json","markdown":"https://secwatch.observer/filing/0001628280-26-001755.md","text":"https://secwatch.observer/filing/0001628280-26-001755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026001755/0001628280-26-001755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026001755/alny-20260111.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:47:03.093820+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}